Startseite>>Signaling Pathways>> Others>>DPA-714

DPA-714

Katalog-Nr.GC38384

DPA-714 ist ein hochaffiner Translokatorprotein(TSPO)-Ligand (Ki=7 nM), der mit einem Fluoratom in seiner Struktur ausgestattet ist, was die Markierung mit Fluor-18 und die In-vivo-Bildgebung mittels Positronen-Emissions-Tomographie ermÖglicht.

Products are for research use only. Not for human use. We do not sell to patients.

DPA-714 Chemische Struktur

Cas No.: 958233-07-3

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
287,00 $
Auf Lager
5mg
261,00 $
Auf Lager
10mg
423,00 $
Auf Lager
50mg
1.170,00 $
Auf Lager
100mg
1.710,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

DPA-714 is a high affinity translocator protein (TSPO) ligand (Ki=7 nM), which is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography. [18F]DPA-714 successfully evaluates for the specific imaging of inflammation in various models of neuroinflammation and in a brain tumor model[1][2].

[1]. James ML, et al. DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med. 2008 May;49(5):814-22. [2]. Harhausen D, et al. Specific imaging of inflammation with the 18 kDa translocator protein ligand DPA-714 in animal models of epilepsy and stroke. PLoS One. 2013 Aug 2;8(8):e69529.

Bewertungen

Review for DPA-714

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DPA-714

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.